Yescarta
FDA approves Kite’s Yescarta therapy for follicular lymphoma
March 9, 2021Manufacturing and Production FDA, Kite, Yescarta
The FDA has granted accelerated approval to Kite’s Yescarta treatment, a medicine for adult patients with relapsed or refractory follicular …
Top Ten most popular articles on Pharmafile.com this week!
August 16, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Air pollution, CAR-T therapy, HIV, Kymriah, Medicare, Novartis, Yescarta, Zolgensma
Novartis’ faulty data scandal dominated the headlines this week, as the Swiss firm faced fierce backlash over covering up the …
Gilead’s CAR-T therapy Yescarta rejected for NHS use in Scotland
February 12, 2019Manufacturing and Production, Sales and Marketing CAR-T, Cancer, Gilead, NHS, Scotland, Yescarta, kite pharma
It’s bad news for Scottish patients living with aggressive forms of non-Hodgkin lymphoma (NHL) as it emerges that the Scottish …
NICE give go-ahead to Gilead’s Yescarta for adults with lymphoma
December 7, 2018Medical Communications Cancer, Cost, Gilead, NHS, NICE, Yescarta, access
The NHS cost effectiveness body NICE has approved Gilead’s Yescarta for treatment of come adults with lymphoma. Gilead’s treatment will …
Gilead’s CAR-T therapy Yescarta shows two-year response duration in large B-cell lymphoma
December 3, 2018Research and Development, Sales and Marketing ASH 2-18, CAR-T, Cancer, Gilead, Yescarta, leukaemia, pharma
Gilead has gone head to head with Novartis at the American Society of Hematology (ASH) Annual Meeting 2018, meeting the …
NHS England appoves Gilead’s CAR T therapy Yescarta
October 5, 2018Medical Communications Gilead, NHS, NICE, UK, Yescarta
Gilead’s CAR T therapy Yescarta is set to be made available on the NHS in England for adults with aggressive …
Novartis’ Kymriah & Gilead’s Yescarta become first EU-approved CAR T therapies
August 28, 2018Manufacturing and Production, Sales and Marketing CAR T, CAR-T, Cancer, EU, Gilead, Kymriah, Novartis, UK, Yescarta, blood cancer, pharma
Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah …
Novartis becomes first to gain second CAR T indication
May 2, 2018Research and Development, Sales and Marketing Gilead, Kymriah, Novartis, Yescarta, biotech, drugs, pharma, pharmaceutical
Novartis has announced that its CAR T treatment, Kymriah, has successfully been given a second indication for the treatment of …
Gilead aims to claim edge with Pfizer CAR-T combo
January 18, 2018Medical Communications, Research and Development Gilead, Kite, Yescarta, biotech, drugs, pharma, pharmaceutical
Although those in pharma often dislike any references to drugs competing with each other for market as in a ‘race’, …
CAR-T is bringing true precision to the fight against cancer
November 1, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Gilead, Kymriah, Novartis, Yescarta
Matt Fellows investigates how the first-ever CAR-T therapy approvals in the past months could mean the field of cancer treatment …
Gilead gets FDA nod for revolutionary blood cancer treatment
October 19, 2017Sales and Marketing CAR-T, Gilead, Yescarta, biotech, drugs, pharma, pharmaceutical
Only weeks after Gilead announced the completion of Kite, it got the news it was hoping for with the FDA’s …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
